Immunomedics Publishes Results on Immunotherapy of Solid

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody

-- T-cell Killing of Human Gastric and Pancreatic Cancer Cell Lines Enhanced With Interferon-α --

MORRIS PLAINS, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq: IMMU ) today announced the publication in Molecular Cancer Therapeutics 1 of an article describing the development of a bispecific antibody, (E1)-3s, that redirects human T cells to certain solid cancers, and its combination with interferon-alpha (IFNα).

Created using the Company's patented DOCK-AND-LOCK ®  protein conjugation technology, (E1)-3s is a bispecific antibody that targets the TROP-2 receptor expressed by many solid cancers and the CD3 antigen present on T cells. The redirecting bispecific antibody was developed for the potential treatment of gastric and pancreatic cancers, since these and various other solid cancers express high-levels of TROP-2. The Company has previously reported the observations that (E1)-3s effectively induces T-cell redirected killing of pancreatic and gastric cancer cell lines. 2 In this new work, however, Company scientists showed the advantage of adding IFNα to this method of immunotherapy.

IFNα has been approval for the treatment of several neoplastic diseases, including patients with resected stage II and III melanoma, in whom it prolongs disease-free survival, and shows a trend toward increased overall survival. Interestingly, to the best of the Company's knowledge, combination therapy with IFNα and a T-cell-redirecting bispecific antibody has not been investigated clinically, or even in animal models.

In the article by Rossi and his colleagues, the effects of IFNα on (E1)-3s-mediated T-cell killing of human gastric and pancreatic cancer cell lines were studied. Adding IFNα to (E1)-3s significantly improved the activity of (E1)-3s in vitro. In an animal model, the combination of IFNα and (E1)-3s delayed the growth of human pancreatic or gastric cancer cells significantly longer than each single agent alone.

More importantly, (E1)-3s was highly active without inducing high-level production of secondary cytokines, thereby reducing the risk of cytokine release syndrome (CRS), also known as cytokine storm, which is often associated with immunotherapy using T-cell-directed antibodies.

"These results suggest that, compared with other T-cell redirecting constructs, our T-cell redirecting bispecific antibody may be less likely to induce CRS, and the addition of IFNα to a therapeutic regimen is not likely to increase this risk," remarked Cynthia L. Sullivan, President and Chief Executive Officer. "This is one of the major new approaches to cancer immunotherapy that we are developing, which may be even more effective in combination with our antibody-drug conjugates currently in clinical trials," she added.

References

  1. Rossi EA, Rossi DL, Cardillo TM, Chang CH and Goldenberg DM. Redirected T-cell killing of solid cancers targeted with an anti-CD3/TROP-2-bispecific antibody is enhanced in combination with interferon-α. Molecular Cancer Therapeutics , vol. 13(10), p. 1-11, 2014.
  2. Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM and Chang CH. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. Mabs , vol. 6, p. 381-391, 2013.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), to whom the Company licensed epratuzumab for the treatment of all non-cancer indications worldwide. UCB expects Phase 3 data in systemic lupus erythematosus in the first half of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with independent cancer study groups. Immunomedics' most advanced candidate to which it retains worldwide rights for all indications is 90 Y-clivatuzumab tetraxetan. The Company initiated a Phase 3 registration trial in January 2014 in patients with advanced pancreatic cancer and expects topline data in mid-2016. Immunomedics' portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics' most advanced ADCs are IMMU-132 and IMMU-130, which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK ® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 257 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedics' strength in intellectual property has resulted in a top-10 ranking in the Biotechnology industry by the Patent Board for the 2014 fiscal year. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Grant Management (973) 605-8200, extension 123

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 112

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 140

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 109

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 100

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 111

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading

Top 5 Most Recently Viewed Articles

SiriusPoint Declares Cash Dividend on Series B Preference Shares

Updated Category News Views 123

SiriusPoint Declares Quarterly Cash Dividend for Investors In a significant move for its shareholders, SiriusPoint Ltd. has recently revealed the approval of a quarterly cash dividend of $0.50 per share for the 8.00% Resettable Fixed Rate Preference Shares, Series B. This decision, endorsed by the Audit Committee of the Board of Directors, showcases the company's...

Continue Reading
Urban One Welcomes New Leadership as CEO David Kantor Retires

Updated Category News Views 435

Changes in Leadership at Urban One Urban One has made a significant announcement regarding changes at the helm of its audio division. Currently, the company bids farewell to CEO David Kantor, a well-respected figure in the industry, whose tenure has shaped Urban One into a key player in audio entertainment. Kantor's retirement, set for early 2025, opens the door for new...

Continue Reading
Mattamy Homes Expands Presence with New Division in Florida

Updated Category News Views 502

Mattamy Homes Expands Operations in Florida Company strengthens regional focus to enhance customer service, empower teams and drive future expansion Mattamy Homes US has officially launched a new division centered in Southwest Florida. This strategic initiative is set to improve operational agility, allowing Mattamy to provide exceptional service to its customers...

Continue Reading
Eloro Resources Secures $3.78 Million in Latest Placement

Updated Category News Views 235

Eloro Resources Completes Private Placement Successfully Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) has announced a significant achievement in its funding efforts. The company successfully closed its non-brokered private placement offering, concluding with a total of 4,200,000 units sold. This move resulted in gross proceeds of approximately $3,780,000,...

Continue Reading
Groundbreaking Global Health Exhibition Set to Transform Healthcare

Updated Category News Views 54

Global Health Exhibition Promises Unmatched Innovation Tomorrow marks the opening of the much-anticipated Global Health Exhibition, an international healthcare event attracting over 100,000 professionals dedicated to health and patient care. Spanning across three days, this premier event will host an impressive assembly of over 1,200 exhibiting companies and brands,...

Continue Reading